¹«Ë¾ÐÂÎÅ
COMPANY NEWS
°²¸´Àû¿Ë?Õü¾ÈÖÎÁÆÇÖÏ®ÐÔÕæ¾ú²¡µÄÕæÊµÌìÏÂÑо¿Ð§¹û
¡¡
Ðû²¼Ê±¼ä£º2026-01-29|
×÷ÕߣºÊ¯Ò©¼¯ÍÅ
½üÆÚ£¬£¬£¬£¬£¬£¬£¬ÓÉ»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃҽԺҩѧ²¿ºÎÑÞ½ÌÊÚºÍÁõ¶«½ÌÊÚΪͨѶ×÷ÕßÔÚ¹ú¼ÊÆÚ¿¯¡¶Drug Design, Development and Therapy¡·½ÒÏþÁËÌâΪ¡°Real-World Outcomes of Amphotericin B Colloidal Dispersion as Salvage Therapy for Invasive Fungal Disease¡±µÄÕæÊµÌìÏÂÑо¿£¬£¬£¬£¬£¬£¬£¬¸ÃÑо¿ÆÀ¹ÀÁËʯҩ¼¯ÍÅÁ½ÐÔÃ¹ËØBµ¨¹Ì´¼ÁòËáõ¥¸´ºÏÎABCD£¬£¬£¬£¬£¬£¬£¬ÉÌÆ·Ãû£º°²¸´Àû¿Ë?£©£¬£¬£¬£¬£¬£¬£¬×÷ΪÕü¾ÈÁÆ·¨ÖÎÁÆÇÖÏ®ÐÔÕæ¾ú²¡µÄÁÆÐ§ÓëÇå¾²ÐÔ£¬£¬£¬£¬£¬£¬£¬ÎªÁÙ´²ÌṩÁËеÄÓÐÁ¦Ö¤¾Ý¡£¡£¡£¡£¡£¡£¡£
Ñо¿Ð§¹û

Ñо¿¸Å¿ö
ÕâÊÇÒ»ÏîÔÚÕæÊµÒ½ÁÆÇéÐÎÖпªÕ¹µÄµ¥ÖÐÐÄ¡¢»ØÊ×ÐÔÑо¿£¬£¬£¬£¬£¬£¬£¬¹²ÄÉÈëÁË2021Äê9ÔÂÖÁ2024Äê2ÔÂʱ´ú60Àý¼ÈÍù½ÓÊÜÈýßòÀà»ò¼¬°×¾úËØÀà¿¹Õæ¾úÖÎÁÆÊ§°Ü»ò²»ÄÍÊܵÄÇÖÏ®ÐÔÕæ¾ú²¡»¼Õß¡£¡£¡£¡£¡£¡£¡£ËùÓл¼ÕßËæºó¾ùʹÓÃABCD¾ÙÐÐÕü¾ÈÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬Ö¼ÔÚÊÓ²ìÆäÔÚÏÖʵÁÙ´²Ó¦ÓÃÖеÄÌåÏÖ¡£¡£¡£¡£¡£¡£¡£
ÔÚÄÉÈëµÄ60Àý»¼ÕßÖУ¬£¬£¬£¬£¬£¬£¬ABCDµÄÁÙ´²Ó¦´ðÂÊΪ71.7%£¨43/60£»£»£»£»£»£»£»95% ÖÃÐÅÇø¼ä[CI]£º59.2%~81.5%£©¡£¡£¡£¡£¡£¡£¡£ABCDµ¥Ò©ÖÎÁƺÍÍŽáÖÎÁƵÄÁÙ´²Ó¦´ðÂÊ»®·ÖΪ74.4%£¨29/39£©ºÍ66.7%£¨14/21£©£¬£¬£¬£¬£¬£¬£¬²î±ðÎÞͳ¼ÆÑ§ÒâÒ壨P=0.528£©¡£¡£¡£¡£¡£¡£¡£¸÷ÑÇ×黼ÕßµÄÁÙ´²Ó¦´ðÂʼûͼ1£¬£¬£¬£¬£¬£¬£¬ÑÇ×éÆÊÎöÏÔʾ£¬£¬£¬£¬£¬£¬£¬ÐԱ𡢻ù´¡¼²²¡¡¢Ñ¬È¾²¿Î»¼°¼ÈÍù¿¹Õæ¾úÖÎÁƾùδ¶ÔÁÆÐ§±¬·¢ÏÔÖøÓ°Ïì¡£¡£¡£¡£¡£¡£¡£¸Î¶¾ÐÔ¡¢Éö¶¾ÐÔºÍÊä×¢Ïà¹Ø·´Ó¦µÄ±¬·¢ÂÊ»®·ÖΪ13.3%¡¢23.3%ºÍ1.7%¡£¡£¡£¡£¡£¡£¡£

ͼ1 ¸÷ÑÇ×黼ÕßµÄÁÙ´²Ó¦´ðÂÊ
ÔÚÕæÊµÌìÏÂÇéÐÎÖУ¬£¬£¬£¬£¬£¬£¬¹ØÓÚ¼ÈÍùßòÀà»ò¼¬°×¾úËØÀàÒ©ÎïÖÎÁÆÊ§°ÜµÄIFD»¼Õߣ¬£¬£¬£¬£¬£¬£¬ABCDÕü¾ÈÖÎÁƾßÓÐÓÅÒìµÄÁÙ´²Ï³¡ºÍ¿É½ÓÊܵÄÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
Jiang M, Li W, Tian L, Xu D, Fan Y, Liu D, He Y. Real-World Outcomes of Amphotericin B Colloidal Dispersion as Salvage Therapy for Invasive Fungal Disease. Drug Des Devel Ther. 2026;20:1-17
ÔÎÄ£º






